Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients

Clinical and Translational Oncology

Volumn 13, Issue 6, 2011, Pages 419-425

  Watanabe, Toshiaki ^a   Kobunai, Takashi ^a,b   Yamamoto, Yoko ^a   Matsuda, Keiji ^a   Ishihara, Soichiro ^a   Nozawa, Keijiro ^a   Iinuma, Hisae ^a   Konishi, Tsuyoshi ^c   Horie, Hisanaga ^d   Ikeuchi, Hiroki ^e   Eshima, Kiyoshi ^b   Muto, Tetsuichiro ^c  

^a TEIKYO UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Colorectal cancer; FOLFOX; Gene expression; Microarray; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; DRUG USE; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC MODEL; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MICROARRAY ANALYSIS; PATIENT SELECTION; PREDICTION; PREDICTIVE VALUE; PRIMARY TUMOR; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79960588906     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0676-z     Document Type: Article

References (30)

1. J. Weitz M. Koch J. Debus, et al. 2005 Colorectal cancer Lancet 365 153 165 15639298 10.1016/S0140-6736(05)17706-X (Pubitemid 40091806)
2. A. de Gramont A. Figer M. Seymour, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 10944126 (Pubitemid 30644117)
3. R.M. Goldberg D.J. Sargent R.F. Morton, et al. 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 14665611 10.1200/JCO.2004.09.046 1:CAS:528: DC%2BD2cXpsVKitbY%3D (Pubitemid 41095110)
4. L.B. Saltz J.V. Cox C. Blanke, et al. 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 905 914 11006366 10.1056/NEJM200009283431302 1:CAS:528: DC%2BD3cXntFOkt7Y%3D
5. J.Y. Douillard D. Cunningham A.D. Roth, et al. 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047 10744089 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D (Pubitemid 30162806)
6. J.W. Adlard S.D. Richman M.T. Seymour, et al. 2002 Prediction of the response of colorectal cancer to systemic therapy Lancet Oncol 3 75 82 11902527 10.1016/S1470-2045(02)00648-4 1:CAS:528:DC%2BD38XitFOjsLY%3D (Pubitemid 34162977)
7. T. Watanabe T.T. Wu P.J. Catalano, et al. 2001 Molecular predictors of survival after adjuvant chemotherapy for colon cancer N Engl J Med 344 1196 1206 11309634 10.1056/NEJM200104193441603 1:CAS:528:DC%2BD3MXjsV2ms74%3D (Pubitemid 32319494)
8. T. Watanabe Y. Komuro T. Kiyomatsu, et al. 2006 Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles Cancer Res 66 3370 3374 16585155 10.1158/0008-5472.CAN-05-3834 1:CAS:528:DC%2BD28XjtVOktrk%3D
9. T. Watanabe T. Kobunai E. Toda, et al. 2006 Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers Cancer Res 66 9804 9808 17047040 10.1158/0008-5472.CAN-06-1163 1:CAS:528:DC%2BD28XhtVyiurzE (Pubitemid 44672030)
10. M. Del Rio F. Molina C. Bascoul-Mollevi, et al. 2007 Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan J Clin Oncol 25 773 780 17327601 10.1200/JCO.2006.07.4187 (Pubitemid 350002876)
11. S.L. Cheeseman S.P. Joel J.D. Chester, et al. 2002 A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer Br J Cancer 87 393 399 12177775 10.1038/sj.bjc.6600467 1:CAS:528:DC%2BD38XmtVOntbY%3D (Pubitemid 34983562)
12. H.S. Hochster L.L. Hart R.K. Ramanathan, et al. 2008 Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 3523 3529 18640933 10.1200/JCO.2007.15.4138 1:CAS:528: DC%2BD1cXpvVWmtLs%3D
13. P. Therasse S.G. Arbuck E.A. Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
14. P. Broberg 2003 Statistical methods for ranking differentially expressed genes Genome Biol 4 R41 12801415 10.1186/gb-2003-4-6-r41
15. T.M. Cover P.E. Hart 1967 Nearest neighbor pattern classification IEEA Trans Inf Theory IT-1 21 27 10.1109/TIT.1967.1053964
16. E. Raymond S. Faivre J.M. Woynarowski, et al. 1998 Oxaliplatin: mechanism of action and antineoplastic activity Semin Oncol 25 4 12 9609103 1:CAS:528:DyaK1cXjvVCkt70%3D (Pubitemid 28248696)
17. D.J. Park J. Stoehlmacher W. Zhang, et al. 2001 A Xerodermapigmentosum group D gene polymorphism predicts clinical outcome to platinumbased chemotherapy in patients with advanced colorectal cancer Cancer Res 61 8654 8658 11751380 1:CAS:528:DC%2BD38Xht1Ogsw%3D%3D (Pubitemid 34013872)
18. J. Stoehlmacher D.J. Park W. Zhang, et al. 2004 A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer 91 344 354 15213713 1:CAS:528:DC%2BD2cXls1eht7o%3D (Pubitemid 39037082)
19. L. Pare E. Marcuello A. Altes, et al. 2008 Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy Br J Cancer 99 1050 1055 18797464 10.1038/sj.bjc.6604671 1:CAS:528:DC%2BD1cXhtFyqt7vP
20. D.J. Park W. Zhang J. Stoehlmacher, et al. 2003 ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy Clin Adv Hematol Oncol 1 162 166 16224397
21. J. Viguier V. Boige C. Miquel, et al. 2005 ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer Clin Cancer Res 11 6212 6217 16144923 10.1158/1078-0432.CCR-04-2216 1:CAS:528: DC%2BD2MXpslans7k%3D (Pubitemid 41262950)
22. A. Ruzzo F. Graziano F. Loupakis, et al. 2007 Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy J Clin Oncol 25 1247 1254 17401013 10.1200/JCO.2006.08.1844 1:CAS:528:DC%2BD2sXkvFyms70%3D (Pubitemid 46640571)
23. E. Martinez-Balibrea A. Abad E. Aranda, et al. 2008 Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer Eur J Cancer 44 1229 1237 18448328 10.1016/j.ejca.2008.03.025 1:CAS:528: DC%2BD1cXmsFKqurY%3D
24. S.H. Kim H.C. Kwon S.Y. Oh, et al. 2009 Prognostic value of ERCC1, thymidylatesynthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer Am J Clin Oncol 32 38 43 19194123 10.1097/COC.0b013e31817be58e 1:CAS:528:DC%2BD1MXhtlGktbs%3D
25. H.C. Kwon M.S. Roh S.Y. Oh, et al. 2007 Prognostic value of expression of ERCC1, thymidylatesynthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer Ann Oncol 18 504 509 17322540 10.1093/annonc/mdl430 (Pubitemid 46359630)
26. Y. Shirota J. Stoehlmacher J. Brabender, et al. 2001 ERCC1 and thymidylatesynthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy J Clin Oncol 19 4298 4304 11731512 1:CAS:528:DC%2BD3MXptlGjtLk%3D (Pubitemid 33096777)
27. D. Arango A.J. Wilson Q. Shi, et al. 2004 Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells Br J Cancer 91 1931 1946 15545975 10.1038/sj.bjc.6602215 1:CAS:528:DC%2BD2cXhtVSqs7nN (Pubitemid 40065523)
28. I. Poola J. Abraham J.J. Marshalleck, et al. 2008 Molecular risk assessment for breast cancer development in patients with ductal hyperplasias Clin Cancer Res 14 1274 1280 18281563 10.1158/1078-0432.CCR-07-4053 1:CAS:528:DC%2BD1cXhvF2nt7c%3D (Pubitemid 351302577)
29. J.X. Tan G.S. Ren G. Tu, et al. 2006 Effect of silencing of hyaluronidase gene HYAL1 by RNA interference on proliferation of human breast cancer cells Ai Zheng 25 844 848 16831275 1:CAS:528:DC%2BD1cXhvFSltA%3D%3D
30. M.H. Corjay M.A. Kearney D.A. Munzer, et al. 1998 Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human Lab Invest 78 847 858 9690562 1:CAS:528:DyaK1cXltlequ78%3D (Pubitemid 28347881)